Soluble guanylyl cyclase α1 and p53 cytoplasmic sequestration and down regulation in prostate cancer

Molecular Endocrinology

Volumn 26, Issue 2, 2012, Pages 292-307

  Cai, Changmeng ^a   Hsieh, Chen Lin ^a   Gao, Shuai ^a   Kannan, Archana ^a   Bhansali, Meenakshi ^a   Govardhan, Kumara ^a   Dutta, Ranendra ^a   Shemshedini, Lirim ^a  

^a UNIVERSITY OF TOLEDO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETOPOSIDE; GUANYLATE CYCLASE; NITRIC OXIDE; PROTEIN P53; SOLUBLE GUANYLYL CYCLASE ALPHA 1; SURVIVIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOPRECIPITATION; INHIBITION KINETICS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION;

APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; CYTOPLASM; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; GUANYLATE CYCLASE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LUCIFERASES; MALE; NITRIC OXIDE; PROSTATIC NEOPLASMS; PROTEIN BINDING; PROTEIN TRANSPORT; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RESPONSE ELEMENTS; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84856280676     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2010-0394     Document Type: Article

References (56)

1. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, Koutcher JA, Scher HI, Ludwig T, Gerald W, Cordon-Cardo C, Pandolfi PP 2005 Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436:725-730.
2. Hussain S, Harris C 2006 p53 Biological network: at the crossroads of the cellular-stress response pathway and molecular carcinogenesis. J Nihon Med Sch 73:54-64.
3. Levine AJ, Momand J, Finlay CA 1991 The p53 tumour suppressor gene. Nature 351:453-456.
4. Hollstein M, Sidransky D, Vogelstein B, Harris CC 1991 p53 mutations in human cancers. Science 253:49-53.
5. Greenblatt MS, Bennett WP, Hollstein M, Harris CC 1994 Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-4878.
6. Qian J, Hirasawa K, Bostwick DG, Bergstralh EJ, Slezak JM, Anderl KL, Borell TJ, Lieber MM, Jenkins RB 2002 Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression. Mod Pathol 15: 35-44.
7. Navone NM, Labate ME, Troncoso P, Pisters LL, Conti CJ, von Eschenbach AC, Logothetis CJ 1999 p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential. J Urol 161:304-308.
8. Zilfou JT, Lowe SW 2009 Tumor suppressive functions of p53. Cold Spring Harb Perspect Biol 1(5):a001883
9. Miyashita T, Reed JC 1995 Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293-299.
10. Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T, Hannon GJ 1995 Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377:552-557.
11. Barak Y, Juven T, Haffner R, Oren M 1993 mdm2 expression is induced by wild type p53 activity. EMBO J 12:461-468.
12. Steele RJ, Thompson AM, Hall PA, Lane DP 1998 The p53 tumour suppressor gene. Br J Surg 85:1460-1467.
13. Moll UM, Riou G, Levine AJ 1992 Two distinct mechanisms alter p53 in breast cancer: Mutation and nuclear exclusion. Proc Natl Acad Sci USA 89:7262-7266.
14. Sengupta S, Harris CC 2005 p53: traffic cop at the crossroads of DNA repair and recombination. Nat Rev Cell Mol Bio 6:44-45.
15. Oh W, Lee EW, Sung YH, Yang MR, Ghim J, Lee HW, Song J 2006 Jab1 induces the cytoplasmic localization and degradation of p53 in coordination with Hdm2. J Biol Chem 281:17457-17465.
16. Nikolaev AY, Li M, Puskas N, Qin J, GuW2003 Parc: a cytoplasmic anchor for p53. Cell 112:29-40.
17. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM 2005 Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310:644-648.
18. Tomlins SA, Mehra R, Rhodes DR, Smith LR, Roulston D, Helgeson BE, Cao X, Wei JT, Rubin MA, Shah RB, Chinnaiyan AM 2006 TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 66:3396-3400.
19. Cai C, Hsieh CL, Omwancha J, Zheng Z, Chen SY, Baert JL, Shemshedini L 2007 ETV1 is a novel androgen receptor-regulated gene that mediates prostate cancer cell invasion. Mol Endocrinol 21:1835-1846.
20. Lei Q, Jiao J, Xin L, Chang C, Wang S, Wu H 2006 NKX3.1 stabilizes p53, inhibits AKT, and blocks prostate cancer initiation caused by PTEN loss. Cancer Cell 9:367-378.
21. Bhatia-Gaur R, Donjacour AA, Sciavolino PJ, Kim M, Desai N, Young P, Norton CR, Gridley T, Cardiff RD, Cunha GR, AbateShen C, ShenMM1999 Roles for Nkx3.1 in prostate development and cancer. Genes Dev 13:966-977.
22. Abdulkadir SA, Magee JA, Peters TJ, Kaleem Z, Naughton CK, Humphrey PA, Milbrandt J 2002 Conditional loss of Nkx3.1 in adult mice induces prostatic intraepithelial neoplasia. Mol Cell Biol 22:1495-1503.
23. Cai C, Chen SY, Zheng Z, Omwancha J, Lin MF, Balk SP, Shemshedini L 2007 Androgen regulation of soluble guanylyl cyclase α1 mediates prostate cancer cell proliferation. Oncogene 26:1606-1615.
24. Korenchuk S, Lehr JE, MClean L, Lee YG, Whitney S, Vessella R, Lin DL, Pienta KJ 2001 VCaP, a cell-based model system of human prostate cancer. In Vivo 15:163-168.
25. Sramkoski RM, Pretlow TG 2nd, Giaconia JM, Pretlow TP, Schwartz S, Sy MS, Marengo SR, Rhim JS, Zhang D, Jacobberger JW 1999 A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim 35:403-409.
26. Igawa T, Lin FF, Lee MS, Karan D, Batra SK, Lin MF 2002 Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model. Prostate 50:222-235.
27. Bataller M, Portugal J 2005 Apoptosis and cell recovery in response to oxidative stress in p53-deficient prostate carcinoma cells. Arch Biochem Biophys 437:151-158.
28. Chen ZJ, Vetter M, Che D, Liu S, Tsai ML, Chang CH 2002 The bradykinin/soluble guanylate cyclase signaling pathway is impaired in androgen-independent prostate cancer cells. Cancer Lett 177: 181-187.
29. Schrammel A, Behrends S, Schmidt K, Koesling D, Mayer B 1996 Characterization of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase. Mol Pharmacol 50:1-5.
30. Haruyama T, Shiino S, Yanagida Y, Kobatake E, Aizawa M 1998 Two types of electrochemical nitric oxide (NO) sensing systems with heat-denatured Cyt C and radical scavenger PTIO. Biosens Bioelectron 13:763-769.
31. Wang X, Wang F, Taniguchi K, Seelan RS, Wang L, Zarfas KE, McDonnell SK, Qian C, Pan K, Lu Y, Shridhar V, Couch FJ, Tindall DJ, Beebe-Dimmer JL, Cooney KA, Isaacs WB, Jacobsen SJ, Schaid DJ, Thibodeau SN, Liu W 2006 Truncating variants in p53AIP1 disrupting DNA damage-induced apoptosis are associated with prostate cancer risk. Cancer Res 66:10302-10307.
32. Pio R, Zudaire I, Pino I, Castaño Z, Zabalegui N, Vicent S, Garcia-Amigot F, Odero MD, Lozano MD, Garcia-Foncillas J, Calasanz MJ, Montuenga LM 2004 α CP-4, encoded by a putative tumor suppressor gene at 3p21, but not its alternative splice variant α CP-4a, is underexpressed in lung cancer. Cancer Res 64:4171-4179.
33. Knauer SK, Mann W, Stauber RH 2007 Survivin's dual role: an export's view. Cell Cycle 6:518-521.
34. Salido M, Vilches J, Roomans GM 2004 Changes in elemental concentrations in LNCaP cells are associated with a protective effect of neuropeptides on etoposide-induced apoptosis. Cell Biol Int 28:397-402.
35. Lecane PS, Kiviharju TM, Sellers RG, Peehl DM 2003 Leptomycin B stabilizes and activates p53 in primary prostatic epithelial cells and induces apoptosis in the LNCaP cell line. Prostate 54:258-267.
36. Logan IR, McNeill HV, Cook S, Lu X, Lunec J, Robson CN 2007 Analysis of the MDM2 antagonist nutlin-3 in human prostate cancer cells. Prostate 67:900-906.
37. Tomkova K, Tomka M, Zajac V 2008 Contribution of p53, p63, and p73 to the developmental diseases and cancer. Neoplasma 55: 177-181.
38. Heidenberg HB, Sesterhenn IA, Gaddipati JP, Weghorst CM, Buzard GS, Moul JW, Srivastava S 1995 Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. J Urol 154:414-421.
39. Dong JT 2006 Prevalent mutations in prostate cancer. J Cell Biochem 97:433-447.
40. Fraser M, Chan SL, Chan SS, Fiscus RR, Tsang BK 2006 Regulation of p53 and suppression of apoptosis by the soluble guanylyl cyclase/cGMP pathway in human ovarian cancer cells. Oncogene 25:2203-2212.
41. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, Nordeen SK, Miller GJ, Lucia MS 2003 Molecular characterization of human prostate carcinoma cell lines. Prostate 57:205-225.
42. Barley RD, Enns L, Paterson MC, Mirzayans R 1998 Aberrant p21WAF1-dependent growth arrest as the possible mechanism of abnormal resistance to ultraviolet light cytotoxicity in Li-Fraumeni syndrome fibroblast strains heterozygous for TP53 mutations. Oncogene 17:533-543.
43. Zhang M, Mukherjee N, Bermudez RS, Latham DE, Delaney MA, Zietman AL, Shipley WU, Chakravarti A 2005 Adenovirus-mediated inhibition of survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo. Prostate 64:293-302.
44. Zhang M, Latham DE, Delaney MA, Chakravarti A 2005 Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene 24:2474-2482.
45. Findley HW, Gu L, Yeager AM, Zhou M 1997 Expression and regulation of Bcl-2, Bcl-xl, and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia. Blood 89:2986-2993.
46. Villunger A, Michalak EM, Coultas L, Müllauer F, Böck G, Ausserlechner MJ, Adams JM, Strasser A 2003 p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 302:1036-1038.
47. Gu J, Zhang L, Swisher SG, Liu J, Roth JA, Fang B 2004 Induction of p53-regulated genes in lung cancer cells: implications of the mechanism for adenoviral p53-mediated apoptosis. Oncogene 23: 1300-1307.
48. Riley T, Sontag E, Chen P, Levine A 2008 Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 9:402-412.
49. Gomes NP, Espinosa JM 2010 Differential regulation of p532 target genes: it's (core promoter) elementary. Genes Dev 24:111-114.
50. Soria C, Estermann FF, Espantman KC, O'Shea CC 2010 Heterochromatin silencing of p53 target genes by a small viral protein. Nature 466:1076-1081.
51. Gurova KV, Rokhlin OW, Budanov AV, Burdelya LG, Chumakov PM, Cohen MB, Gudkov AV 2003 Cooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells. Cancer Res 63:2905-2912.
52. Lee EW, Oh W, Song J 2006 Jab1 as a mediator of nuclear export and cytoplasmic degradation of p53. Mol Cells 22:133-140.
53. Zhang XC, Chen J, Su CH, Yang HY, Lee MH 2008 Roles for CSN5 in control of p53/MDM2 activities. J Cell Biochem 103: 1219-1230.
54. Li M, Brooks CL, Wu-Baer F, Chen D, Baer R, GuW2003 Monoversus polyubiquitination: differential control of p53 fate by Mdm2. Science 302:1972-1975.
55. Shenk JL, Fisher CJ, Chen SY, Zhou XF, Tillman K, Shemshedini L 2001 p53 represses androgen-induced transactivation of prostatespecific antigen by disrupting hAR amino- to carboxyl-terminal interaction. J Biol Chem 276:38472-38479.
56. Cai C, Hsieh CL, Shemshedini L 2007 c-Jun has multiple enhancing activities in the novel cross talk between the androgen receptor and Ets variant gene 1 in prostate cancer. Mol Cancer Res 5:725-735